Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  pazopanib hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 93 for your search:
Start Over
VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 113971, NCT01205230
Adjuvant Pazopanib in Stage I NSCLC
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: IFCT-0703, Eudract : 2008-004897-41, NCT00775307
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG105192, NCT00334282
Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG107769, NCT00387764
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 108844, NCT00720941
Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG110727, NCT00753688
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 110655, NCT00866697
Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 113046, NCT01064310
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 113387, NCT01235962
Pazopanib and Vinflunine in Urothelial Cancer of the Bladder
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: DZITM1, NCT01265940
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG102616, UCLA-0508053-01, UCLA-0506058-01, GSK-VEG102616, NCT00244764
Phase II Study of GW786034 in Patients With Relapsed or Refractory Advanced or Metastatic Soft Tissue Sarcoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: EORTC-62043, GSK-EORTC-62043, EUDRACT-2004-004378-10, NCT00297258
Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG20006, NCT00256880
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 104450, NCT00281632
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG20007, NCT00347919
Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG102857, NCT00350727
Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG105290, NCT00367679
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VEG105281, NCT00430781
Pazopanib in Treating Patients With Advanced Neuroendocrine Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00201, CDR0000537034, MDACC 2006-0077, 7650, U01CA062490, P30CA016672, N01CM62202, MDA-2006-0077, NCT00454363
Phase II Study of Pazopanib Hydrochloride in Patients With Stage IV or Recurrent Nasopharyngeal Carcinoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CTRG-NP05/25/06, 7623, SINGAPORE-NCC-06-01, NCC-06-01, NCT00454142
Pazopanib in Treating Patients With Recurrent Glioblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02710, NABTC-0602, U01CA062399, CDR0000538083, 737754, NCI-07-C-0138, NCT00459381
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00202, N01CM62201, CDR0000538086, 14954A, UCCRC-14954A, 7659, NCT00454571
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00656, CDR0000539269, N0623, U10CA025224, NCCTG-N0623, NCT00459862
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00203, CDR0000543460, MAYO-MC0553, MC0553, 7661, N01CM62205, NCT00471536
Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00200, PMH-PHL-058, PMH-10036920, CDR0000549528, PHL-058, 7640, N01CM00032, N01CM62203, NCT00486642
Start Over